2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells

The Prostate
Alba MinelliZoran Culig

Abstract

Docetaxel-based chemotherapy is the only treatment that demonstrated an overall survival benefit in men with hormone refractory prostate cancer. 2-CADO inhibits the growth of PC3 cells by inducing apoptosis and cell cycle arrest through a mechanism that involves cellular uptake. Androgen-independent and -sensitive (PC3 and LNCaP) prostate cancer cells and non-neoplastic HECV cells were used in the study. Proliferation and cell cycle progression were analyzed in the presence of 2-CADO and Docetaxel. Invasive potential was assessed by soft agar assay and metastatic ability by adhesion assay. IL-23 and PAR-1 expression were determined by real time PCR. 2-CADO pre-treatment followed by Docetaxel at subclinical dosage reduced the viability of either PC3 or LNCaP while it did not enhance Docetaxel-induced cytotoxicity in adherent non-neoplastic HECV. The drugs reduced the invasive potential of PC3 cells by inducing apoptosis and blocking cell cycle progression in the S-phase. Down-regulation of PAR-1 gene expression resulted in a slightly lower metastatic potential, whereas up-regulation of IL-23 induced the activation of the immune system. Pretreatment of PC3 cells with 2-CADO decreased the effective concentration of Docetaxel, lowe...Continue Reading

References

Jun 1, 1995·British Journal of Cancer·C HennequinV Favaudon
Oct 23, 1997·Cell Biochemistry and Function·P LocciN Staffolani
Nov 6, 1998·Trends in Pharmacological Sciences·M Pastor-AngladaF J Casado
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristine R CrewsRaul C Ribeiro
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grant R GoodmanAlan Saven
May 27, 2003·International Journal of Cancer. Journal International Du Cancer·Yan-Qing WangMasatoshi Tagawa
Jul 9, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chia-Hui LoMi-Hua Tao
Sep 25, 2003·International Journal of Cancer. Journal International Du Cancer·Stanislav ZelivianskiMing-Fong Lin
Oct 9, 2003·The Journal of Urology·Masood A KhanAlan W Partin
Nov 25, 2003·Apoptosis : an International Journal on Programmed Cell Death·K A JacobsonM P Abbracchio
Dec 10, 2003·Oncogene·Deepa SampathWilliam Plunkett
Feb 6, 2004·Biochemical Pharmacology·Nadia D'AmbrosiCinzia Volonté
Jul 30, 2005·Journal of Cellular Biochemistry·Kwanchanit TantivejkulKenneth J Pienta
Oct 26, 2005·The Prostate·Varsha KaushalPerkins Mukunyadzi
Mar 21, 2006·International Immunopharmacology·Paula Fernández-CalottiMirta Giordano
Mar 25, 2006·Future Oncology·D C Gilbert, C Parker
Jun 3, 2006·The Prostate·Alba MinelliZoran Culig
Jul 3, 2007·Expert Opinion on Emerging Drugs·Pavlos MsaouelMichael Koutsilieris

❮ Previous
Next ❯

Citations

Oct 11, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Letizia MezzasomaIlaria Bellezza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis